{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:41:21Z","timestamp":1793943681637,"version":"4.8.0"},"reference-count":128,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T00:00:00Z","timestamp":1695859200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007949","name":"Swedish Rheumatism Association","doi-asserted-by":"publisher","award":["R-969696"],"award-info":[{"award-number":["R-969696"]}],"id":[{"id":"10.13039\/501100007949","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007949","name":"Swedish Rheumatism Association","doi-asserted-by":"publisher","award":["FAI-2020-0741"],"award-info":[{"award-number":["FAI-2020-0741"]}],"id":[{"id":"10.13039\/501100007949","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007949","name":"Swedish Rheumatism Association","doi-asserted-by":"publisher","award":["SLS-974449"],"award-info":[{"award-number":["SLS-974449"]}],"id":[{"id":"10.13039\/501100007949","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007949","name":"Swedish Rheumatism Association","doi-asserted-by":"publisher","award":["OLL-974804"],"award-info":[{"award-number":["OLL-974804"]}],"id":[{"id":"10.13039\/501100007949","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007949","name":"Swedish Rheumatism Association","doi-asserted-by":"publisher","award":["2021-00436"],"award-info":[{"award-number":["2021-00436"]}],"id":[{"id":"10.13039\/501100007949","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007949","name":"Swedish Rheumatism Association","doi-asserted-by":"publisher","award":["2021-26"],"award-info":[{"award-number":["2021-26"]}],"id":[{"id":"10.13039\/501100007949","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007949","name":"Swedish Rheumatism Association","doi-asserted-by":"publisher","award":["FoUI-955483"],"award-info":[{"award-number":["FoUI-955483"]}],"id":[{"id":"10.13039\/501100007949","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007949","name":"Swedish Rheumatism Association","doi-asserted-by":"publisher","award":["82003364"],"award-info":[{"award-number":["82003364"]}],"id":[{"id":"10.13039\/501100007949","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007949","name":"Swedish Rheumatism Association","doi-asserted-by":"publisher","award":["2023JJ40827"],"award-info":[{"award-number":["2023JJ40827"]}],"id":[{"id":"10.13039\/501100007949","id-type":"DOI","asserted-by":"publisher"}]},{"name":"King Gustaf V\u2019s 80-year Foundation","award":["R-969696"],"award-info":[{"award-number":["R-969696"]}]},{"name":"King Gustaf V\u2019s 80-year Foundation","award":["FAI-2020-0741"],"award-info":[{"award-number":["FAI-2020-0741"]}]},{"name":"King Gustaf V\u2019s 80-year Foundation","award":["SLS-974449"],"award-info":[{"award-number":["SLS-974449"]}]},{"name":"King Gustaf V\u2019s 80-year Foundation","award":["OLL-974804"],"award-info":[{"award-number":["OLL-974804"]}]},{"name":"King Gustaf V\u2019s 80-year Foundation","award":["2021-00436"],"award-info":[{"award-number":["2021-00436"]}]},{"name":"King Gustaf V\u2019s 80-year Foundation","award":["2021-26"],"award-info":[{"award-number":["2021-26"]}]},{"name":"King Gustaf V\u2019s 80-year Foundation","award":["FoUI-955483"],"award-info":[{"award-number":["FoUI-955483"]}]},{"name":"King Gustaf V\u2019s 80-year Foundation","award":["82003364"],"award-info":[{"award-number":["82003364"]}]},{"name":"King Gustaf V\u2019s 80-year Foundation","award":["2023JJ40827"],"award-info":[{"award-number":["2023JJ40827"]}]},{"DOI":"10.13039\/501100007687","name":"Swedish Society of Medicine","doi-asserted-by":"publisher","award":["R-969696"],"award-info":[{"award-number":["R-969696"]}],"id":[{"id":"10.13039\/501100007687","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007687","name":"Swedish Society of Medicine","doi-asserted-by":"publisher","award":["FAI-2020-0741"],"award-info":[{"award-number":["FAI-2020-0741"]}],"id":[{"id":"10.13039\/501100007687","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007687","name":"Swedish Society of Medicine","doi-asserted-by":"publisher","award":["SLS-974449"],"award-info":[{"award-number":["SLS-974449"]}],"id":[{"id":"10.13039\/501100007687","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007687","name":"Swedish Society of Medicine","doi-asserted-by":"publisher","award":["OLL-974804"],"award-info":[{"award-number":["OLL-974804"]}],"id":[{"id":"10.13039\/501100007687","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007687","name":"Swedish Society of Medicine","doi-asserted-by":"publisher","award":["2021-00436"],"award-info":[{"award-number":["2021-00436"]}],"id":[{"id":"10.13039\/501100007687","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007687","name":"Swedish Society of Medicine","doi-asserted-by":"publisher","award":["2021-26"],"award-info":[{"award-number":["2021-26"]}],"id":[{"id":"10.13039\/501100007687","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007687","name":"Swedish Society of Medicine","doi-asserted-by":"publisher","award":["FoUI-955483"],"award-info":[{"award-number":["FoUI-955483"]}],"id":[{"id":"10.13039\/501100007687","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007687","name":"Swedish Society of Medicine","doi-asserted-by":"publisher","award":["82003364"],"award-info":[{"award-number":["82003364"]}],"id":[{"id":"10.13039\/501100007687","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007687","name":"Swedish Society of Medicine","doi-asserted-by":"publisher","award":["2023JJ40827"],"award-info":[{"award-number":["2023JJ40827"]}],"id":[{"id":"10.13039\/501100007687","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Nyckelfonden","award":["R-969696"],"award-info":[{"award-number":["R-969696"]}]},{"name":"Nyckelfonden","award":["FAI-2020-0741"],"award-info":[{"award-number":["FAI-2020-0741"]}]},{"name":"Nyckelfonden","award":["SLS-974449"],"award-info":[{"award-number":["SLS-974449"]}]},{"name":"Nyckelfonden","award":["OLL-974804"],"award-info":[{"award-number":["OLL-974804"]}]},{"name":"Nyckelfonden","award":["2021-00436"],"award-info":[{"award-number":["2021-00436"]}]},{"name":"Nyckelfonden","award":["2021-26"],"award-info":[{"award-number":["2021-26"]}]},{"name":"Nyckelfonden","award":["FoUI-955483"],"award-info":[{"award-number":["FoUI-955483"]}]},{"name":"Nyckelfonden","award":["82003364"],"award-info":[{"award-number":["82003364"]}]},{"name":"Nyckelfonden","award":["2023JJ40827"],"award-info":[{"award-number":["2023JJ40827"]}]},{"name":"Professor Nanna Svartz Foundation","award":["R-969696"],"award-info":[{"award-number":["R-969696"]}]},{"name":"Professor Nanna Svartz Foundation","award":["FAI-2020-0741"],"award-info":[{"award-number":["FAI-2020-0741"]}]},{"name":"Professor Nanna Svartz Foundation","award":["SLS-974449"],"award-info":[{"award-number":["SLS-974449"]}]},{"name":"Professor Nanna Svartz Foundation","award":["OLL-974804"],"award-info":[{"award-number":["OLL-974804"]}]},{"name":"Professor Nanna Svartz Foundation","award":["2021-00436"],"award-info":[{"award-number":["2021-00436"]}]},{"name":"Professor Nanna Svartz Foundation","award":["2021-26"],"award-info":[{"award-number":["2021-26"]}]},{"name":"Professor Nanna Svartz Foundation","award":["FoUI-955483"],"award-info":[{"award-number":["FoUI-955483"]}]},{"name":"Professor Nanna Svartz Foundation","award":["82003364"],"award-info":[{"award-number":["82003364"]}]},{"name":"Professor Nanna Svartz Foundation","award":["2023JJ40827"],"award-info":[{"award-number":["2023JJ40827"]}]},{"name":"Ulla and Roland Gustafsson Foundation","award":["R-969696"],"award-info":[{"award-number":["R-969696"]}]},{"name":"Ulla and Roland Gustafsson Foundation","award":["FAI-2020-0741"],"award-info":[{"award-number":["FAI-2020-0741"]}]},{"name":"Ulla and Roland Gustafsson Foundation","award":["SLS-974449"],"award-info":[{"award-number":["SLS-974449"]}]},{"name":"Ulla and Roland Gustafsson Foundation","award":["OLL-974804"],"award-info":[{"award-number":["OLL-974804"]}]},{"name":"Ulla and Roland Gustafsson Foundation","award":["2021-00436"],"award-info":[{"award-number":["2021-00436"]}]},{"name":"Ulla and Roland Gustafsson Foundation","award":["2021-26"],"award-info":[{"award-number":["2021-26"]}]},{"name":"Ulla and Roland Gustafsson Foundation","award":["FoUI-955483"],"award-info":[{"award-number":["FoUI-955483"]}]},{"name":"Ulla and Roland Gustafsson Foundation","award":["82003364"],"award-info":[{"award-number":["82003364"]}]},{"name":"Ulla and Roland Gustafsson Foundation","award":["2023JJ40827"],"award-info":[{"award-number":["2023JJ40827"]}]},{"name":"Region Stockholm","award":["R-969696"],"award-info":[{"award-number":["R-969696"]}]},{"name":"Region Stockholm","award":["FAI-2020-0741"],"award-info":[{"award-number":["FAI-2020-0741"]}]},{"name":"Region Stockholm","award":["SLS-974449"],"award-info":[{"award-number":["SLS-974449"]}]},{"name":"Region Stockholm","award":["OLL-974804"],"award-info":[{"award-number":["OLL-974804"]}]},{"name":"Region Stockholm","award":["2021-00436"],"award-info":[{"award-number":["2021-00436"]}]},{"name":"Region Stockholm","award":["2021-26"],"award-info":[{"award-number":["2021-26"]}]},{"name":"Region Stockholm","award":["FoUI-955483"],"award-info":[{"award-number":["FoUI-955483"]}]},{"name":"Region Stockholm","award":["82003364"],"award-info":[{"award-number":["82003364"]}]},{"name":"Region Stockholm","award":["2023JJ40827"],"award-info":[{"award-number":["2023JJ40827"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["R-969696"],"award-info":[{"award-number":["R-969696"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["FAI-2020-0741"],"award-info":[{"award-number":["FAI-2020-0741"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["SLS-974449"],"award-info":[{"award-number":["SLS-974449"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["OLL-974804"],"award-info":[{"award-number":["OLL-974804"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["2021-00436"],"award-info":[{"award-number":["2021-00436"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["2021-26"],"award-info":[{"award-number":["2021-26"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["FoUI-955483"],"award-info":[{"award-number":["FoUI-955483"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82003364"],"award-info":[{"award-number":["82003364"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["2023JJ40827"],"award-info":[{"award-number":["2023JJ40827"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Hunan Provincial Natural Science Foundation of China","award":["R-969696"],"award-info":[{"award-number":["R-969696"]}]},{"name":"Hunan Provincial Natural Science Foundation of China","award":["FAI-2020-0741"],"award-info":[{"award-number":["FAI-2020-0741"]}]},{"name":"Hunan Provincial Natural Science Foundation of China","award":["SLS-974449"],"award-info":[{"award-number":["SLS-974449"]}]},{"name":"Hunan Provincial Natural Science Foundation of China","award":["OLL-974804"],"award-info":[{"award-number":["OLL-974804"]}]},{"name":"Hunan Provincial Natural Science Foundation of China","award":["2021-00436"],"award-info":[{"award-number":["2021-00436"]}]},{"name":"Hunan Provincial Natural Science Foundation of China","award":["2021-26"],"award-info":[{"award-number":["2021-26"]}]},{"name":"Hunan Provincial Natural Science Foundation of China","award":["FoUI-955483"],"award-info":[{"award-number":["FoUI-955483"]}]},{"name":"Hunan Provincial Natural Science Foundation of China","award":["82003364"],"award-info":[{"award-number":["82003364"]}]},{"name":"Hunan Provincial Natural Science Foundation of China","award":["2023JJ40827"],"award-info":[{"award-number":["2023JJ40827"]}]},{"name":"Scientific Research Launch Project for new employees of the Second Xiangya Hospital of Central South University","award":["R-969696"],"award-info":[{"award-number":["R-969696"]}]},{"name":"Scientific Research Launch Project for new employees of the Second Xiangya Hospital of Central South University","award":["FAI-2020-0741"],"award-info":[{"award-number":["FAI-2020-0741"]}]},{"name":"Scientific Research Launch Project for new employees of the Second Xiangya Hospital of Central South University","award":["SLS-974449"],"award-info":[{"award-number":["SLS-974449"]}]},{"name":"Scientific Research Launch Project for new employees of the Second Xiangya Hospital of Central South University","award":["OLL-974804"],"award-info":[{"award-number":["OLL-974804"]}]},{"name":"Scientific Research Launch Project for new employees of the Second Xiangya Hospital of Central South University","award":["2021-00436"],"award-info":[{"award-number":["2021-00436"]}]},{"name":"Scientific Research Launch Project for new employees of the Second Xiangya Hospital of Central South University","award":["2021-26"],"award-info":[{"award-number":["2021-26"]}]},{"name":"Scientific Research Launch Project for new employees of the Second Xiangya Hospital of Central South University","award":["FoUI-955483"],"award-info":[{"award-number":["FoUI-955483"]}]},{"name":"Scientific Research Launch Project for new employees of the Second Xiangya Hospital of Central South University","award":["82003364"],"award-info":[{"award-number":["82003364"]}]},{"name":"Scientific Research Launch Project for new employees of the Second Xiangya Hospital of Central South University","award":["2023JJ40827"],"award-info":[{"award-number":["2023JJ40827"]}]},{"name":"Karolinska Institutet","award":["R-969696"],"award-info":[{"award-number":["R-969696"]}]},{"name":"Karolinska Institutet","award":["FAI-2020-0741"],"award-info":[{"award-number":["FAI-2020-0741"]}]},{"name":"Karolinska Institutet","award":["SLS-974449"],"award-info":[{"award-number":["SLS-974449"]}]},{"name":"Karolinska Institutet","award":["OLL-974804"],"award-info":[{"award-number":["OLL-974804"]}]},{"name":"Karolinska Institutet","award":["2021-00436"],"award-info":[{"award-number":["2021-00436"]}]},{"name":"Karolinska Institutet","award":["2021-26"],"award-info":[{"award-number":["2021-26"]}]},{"name":"Karolinska Institutet","award":["FoUI-955483"],"award-info":[{"award-number":["FoUI-955483"]}]},{"name":"Karolinska Institutet","award":["82003364"],"award-info":[{"award-number":["82003364"]}]},{"name":"Karolinska Institutet","award":["2023JJ40827"],"award-info":[{"award-number":["2023JJ40827"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Systemic Lupus Erythematosus (SLE) is a chronic systemic autoimmune disease of high clinical and molecular heterogeneity, and a relapsing-remitting pattern. The disease is currently without cure and more prevalent in women. B cell tolerance and production of autoantibodies are critical mechanisms that drive SLE pathophysiology. However, how the balance of the immune system is broken and how the innate and adaptive immune systems are interacting during lupus-specific autoimmune responses are still largely unknown. Here, we review the latest knowledge on B cell development, maturation, and central versus peripheral tolerance in connection to SLE and treatment options. We also discuss the regulation of B cells by conventional T cells, granulocytes, and unconventional T cells, and how effector B cells exert their functions in SLE. We also discuss mechanisms of action of B cell-targeted therapies, as well as possible future directions based on current knowledge of B cell biology.<\/jats:p>","DOI":"10.3390\/jcm12196268","type":"journal-article","created":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T07:50:26Z","timestamp":1695887426000},"page":"6268","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["B Cell Tolerance and Targeted Therapies in SLE"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4875-5395","authenticated-orcid":false,"given":"Ioannis","family":"Parodis","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, 17177 Stockholm, Sweden"},{"name":"Department of Gastroenterology, Dermatology and Rheumatology, Karolinska University Hospital, 17176 Stockholm, Sweden"},{"name":"Department of Rheumatology, Faculty of Medicine and Health, \u00d6rebro University, 70281 \u00d6rebro, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Long","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hunan Key Laboratory of Medical Epigenomics, Second Xiangya Hospital, Central South University, Changsha 410011, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikael C. I.","family":"Karlsson","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, 17177 Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8935-5187","authenticated-orcid":false,"given":"Xin","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hunan Key Laboratory of Medical Epigenomics, Second Xiangya Hospital, Central South University, Changsha 410011, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,9,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1136\/annrheumdis-2020-218272","article-title":"Update omicronn the diagnosis and management of systemic lupus erythematosus","volume":"80","author":"Fanouriakis","year":"2021","journal-title":"Ann. Rheum Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1042\/BCJ20180565","article-title":"Signalling circuits that direct early B-cell development","volume":"476","author":"Petkau","year":"2019","journal-title":"Biochem. J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e20202001","DOI":"10.1084\/jem.20202001","article-title":"Human marginal zone B cell development from early T2 progenitors","volume":"218","author":"Tull","year":"2021","journal-title":"J. Exp. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1146\/annurev.immunol.021908.132541","article-title":"B cell signaling and fate decision","volume":"28","author":"Kurosaki","year":"2010","journal-title":"Annu. Rev. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"dev199373","DOI":"10.1242\/dev.199373","article-title":"B1 lymphocytes develop independently of Notch signaling during mouse embryonic development","volume":"148","author":"Scarfo","year":"2021","journal-title":"Development"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.coi.2018.12.001","article-title":"B-1 cell responses to infections","volume":"57","author":"Smith","year":"2019","journal-title":"Curr. Opin. Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0037-1963(00)90113-6","article-title":"The spleen: Anatomy and anatomical function","volume":"37","author":"Chadburn","year":"2000","journal-title":"Semin Hematol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.3389\/fimmu.2018.02469","article-title":"Regulation of the Germinal Center Response","volume":"9","author":"Stebegg","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1615\/CritRevImmunol.2018024985","article-title":"Heterogeneity of Memory Marginal Zone B Cells","volume":"38","author":"Hendricks","year":"2018","journal-title":"Crit. Rev. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/s41577-020-00446-2","article-title":"Transcriptional regulation of memory B cell differentiation","volume":"21","author":"Laidlaw","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2015.06.001","article-title":"BAFF-driven autoimmunity requires CD19 expression","volume":"62","author":"Fairfax","year":"2015","journal-title":"J. Autoimmun."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.immuni.2006.07.010","article-title":"Alternative and classical NF-kappa B signaling retain autoreactive B cells in the splenic marginal zone and result in lupus-like disease","volume":"25","author":"Enzler","year":"2006","journal-title":"Immunity"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/nri.2017.19","article-title":"Mechanisms of central tolerance for B cells","volume":"17","author":"Nemazee","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/clim.2002.5290","article-title":"Role of receptor revision in forming a B cell repertoire","volume":"105","author":"Seagal","year":"2002","journal-title":"Clin. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/imr.12821","article-title":"Impaired B-cell tolerance checkpoints promote the development of autoimmune diseases and pathogenic autoantibodies","volume":"292","author":"Meffre","year":"2019","journal-title":"Immunol. Rev."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/imr.12808","article-title":"Clonal redemption and clonal anergy as mechanisms to balance B cell tolerance and immunity","volume":"292","author":"Burnett","year":"2019","journal-title":"Immunol. Rev."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.it.2010.03.002","article-title":"Activation of B cells by antigens on follicular dendritic cells","volume":"31","author":"Sukumar","year":"2010","journal-title":"Trends Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1146\/annurev.immunol.23.021704.115723","article-title":"Maintenance of serum antibody levels","volume":"23","author":"Manz","year":"2005","journal-title":"Annu. Rev. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.cell.2017.07.026","article-title":"Clonal Evolution of Autoreactive Germinal Centers","volume":"170","author":"Degn","year":"2017","journal-title":"Cell"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"23671","DOI":"10.1073\/pnas.1910097116","article-title":"Sterile activation of invariant natural killer T cells by ER-stressed antigen-presenting cells","volume":"116","author":"Bedard","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nri844","article-title":"BAFF: A fundamental survival factor for B cells","volume":"2","author":"Mackay","year":"2002","journal-title":"Nat. Rev. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/ni.2194","article-title":"B cell-helper neutrophils stimulate the diversification and production of immunoglobulin in the marginal zone of the spleen","volume":"13","author":"Puga","year":"2011","journal-title":"Nat. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"102736","DOI":"10.1016\/j.autrev.2020.102736","article-title":"B cell activating factor (BAFF): Structure, functions, autoimmunity and clinical implications in Systemic Lupus Erythematosus (SLE)","volume":"20","author":"Mockel","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e000061","DOI":"10.1136\/lupus-2014-000061","article-title":"Evaluation of B lymphocyte stimulator and a proliferation inducing ligand as candidate biomarkers in lupus nephritis based on clinical and histopathological outcome following induction therapy","volume":"2","author":"Parodis","year":"2015","journal-title":"Lupus Sci. Med."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Petri, M., Fu, W., Ranger, A., Allaire, N., Cullen, P., Magder, L.S., and Zhang, Y. (2019). Association between changes in gene signatures expression and disease activity among patients with systemic lupus erythematosus. BMC Med. Genom., 12.","DOI":"10.1186\/s12920-018-0468-1"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1038\/ni.3583","article-title":"Neutrophils license iNKT cells to regulate self-reactive mouse B cell responses","volume":"17","author":"Hagglof","year":"2016","journal-title":"Nat. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/ni.2511","article-title":"Innate B cell helpers reveal novel types of antibody responses","volume":"14","author":"Vinuesa","year":"2013","journal-title":"Nat. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.coi.2021.06.012","article-title":"Keeping up with the stress of antibody production: BAFF and APRIL maintain memory plasma cells","volume":"71","author":"Cornelis","year":"2021","journal-title":"Curr. Opin. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/nri3857","article-title":"Antibody-independent functions of B cells: A focus on cytokines","volume":"15","author":"Shen","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/intimm\/dxv028","article-title":"Innate response activator B cells: Origins and functions","volume":"27","author":"Chousterman","year":"2015","journal-title":"Int. Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41584-020-00544-4","article-title":"Toll-like receptor signalling in B cells during systemic lupus erythematosus","volume":"17","author":"Fillatreau","year":"2021","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.immuni.2018.08.015","article-title":"Distinct Effector B Cells Induced by Unregulated Toll-like Receptor 7 Contribute to Pathogenic Responses in Systemic Lupus Erythematosus","volume":"49","author":"Jenks","year":"2018","journal-title":"Immunity"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1038\/s41467-018-03750-7","article-title":"IL-21 drives expansion and plasma cell differentiation of autoreactive CD11chiT-bet+ B cells in SLE","volume":"9","author":"Wang","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.coi.2019.07.008","article-title":"Molecular pattern recognition in peripheral B cell tolerance: Lessons from age-associated B cells","volume":"61","author":"Johnson","year":"2019","journal-title":"Curr. Opin. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1172\/JCI91250","article-title":"B cells expressing the transcription factor T-bet drive lupus-like autoimmunity","volume":"127","author":"Rubtsova","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1172\/JCI85113","article-title":"Human regulatory B cells in health and disease: Therapeutic potential","volume":"127","author":"Mauri","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.immuni.2009.11.009","article-title":"CD19+CD24hiCD38hi B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients","volume":"32","author":"Blair","year":"2010","journal-title":"Immunity"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.immuni.2016.02.012","article-title":"A Regulatory Feedback between Plasmacytoid Dendritic Cells and Regulatory B Cells Is Aberrant in Systemic Lupus Erythematosus","volume":"44","author":"Menon","year":"2016","journal-title":"Immunity"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"312","DOI":"10.3109\/03009742.2015.1126346","article-title":"Decreased IL-10+ regulatory B cells (Bregs) in lupus nephritis patients","volume":"45","author":"Heinemann","year":"2016","journal-title":"Scand. J. Rheumatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.immuni.2012.02.008","article-title":"Lipid-antigen presentation by CD1d+ B cells is essential for the maintenance of invariant natural killer T cells","volume":"36","author":"Bosma","year":"2012","journal-title":"Immunity"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/nri.2017.1","article-title":"Immune regulation by glucocorticoids","volume":"17","author":"Cain","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1093\/intimm\/dxh230","article-title":"Early lymphoid progenitors in mouse and man are highly sensitive to glucocorticoids","volume":"17","author":"Igarashi","year":"2005","journal-title":"Int. Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clim.2018.07.003","article-title":"Hydroxychloroquine efficiently suppresses inflammatory responses of human class-switched memory B cells via Toll-like receptor 9 inhibition","volume":"195","author":"Torigoe","year":"2018","journal-title":"Clin. Immunol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","article-title":"2019 update of the EULAR recommendations for the management of systemic lupus erythematosus","volume":"78","author":"Fanouriakis","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1358\/dot.2009.45.7.1384878","article-title":"Mycophenolate mofetil: An update","volume":"45","author":"Villarroel","year":"2009","journal-title":"Drugs Today"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13075-015-0603-8","article-title":"Differential effects of cyclophosphamide and mycophenolate mofetil on cellular and serological parameters in patients with systemic lupus erythematosus","volume":"17","author":"Fassbinder","year":"2015","journal-title":"Arthritis Res. Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.it.2013.07.006","article-title":"Dendritic cells and other innate determinants of T helper cell polarisation","volume":"34","author":"Walsh","year":"2013","journal-title":"Trends Immunol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1002\/eji.1830121207","article-title":"Effects of cyclosporin A on the immune system of the mouse. I. Evidence for a direct selective effect of cyclosporin A on B cells responding to anti-immunoglobulin antibodies","volume":"12","author":"Dongworth","year":"1982","journal-title":"Eur. J. Immunol."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Hilchey, S.P., Palshikar, M.G., Emo, J.A., Li, D., Garigen, J., Wang, J., Mendelson, E.S., Cipolla, V., Thakar, J., and Zand, M.S. (2020). Cyclosporine a directly affects human and mouse b cell migration in vitro by disrupting a hIF-1 \u03b1dependent, o2 sensing, molecular switch. BMC Immunol., 21.","DOI":"10.1186\/s12865-020-0342-8"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/0008-8749(92)90028-N","article-title":"Effects of IL-4, IL-5, and IL-6 on growth and immunoglobulin production of Epstein-Barr virus-infected human B cells","volume":"143","author":"Bende","year":"1992","journal-title":"Cell Immunol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0896-8411(92)90031-K","article-title":"The effects of cyclosporin A on non-T cell components of the immune system","volume":"5","author":"Thomson","year":"1992","journal-title":"J. Autoimmun."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.autrev.2015.09.006","article-title":"Tacrolimus use in lupus nephritis: A systematic review and meta-analysis","volume":"15","author":"Hannah","year":"2016","journal-title":"Autoimmun. Rev."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.trim.2014.03.003","article-title":"Decrease of immature B cell and interleukin-10 during early-post-transplant period in renal transplant recipients under tacrolimus based immunosuppression","volume":"30","author":"Chung","year":"2014","journal-title":"Transpl. Immunol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.1016\/j.transproceed.2019.08.039","article-title":"Inhibition of T Helper Cell Differentiation by Tacrolimus or Sirolimus Results in Reduced B-Cell Activation: Effects on T Follicular Helper Cells","volume":"51","author":"Kraaijeveld","year":"2019","journal-title":"Transplant. Proc."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1365-2249.2009.04051.x","article-title":"Calcineurin inhibitors affect B cell antibody responses indirectly by interfering with T cell help","volume":"159","author":"Heidt","year":"2010","journal-title":"Clin. Exp. Immunol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.molimm.2017.07.001","article-title":"Methotrexate, combined with cyclophosphamide attenuates murine collagen induced arthritis by modulating the expression level of Breg and DCs","volume":"90","author":"Fan","year":"2017","journal-title":"Mol. Immunol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12013-008-9036-1","article-title":"The BLyS family: Toward a molecular understanding of B cell homeostasis","volume":"53","author":"Treml","year":"2009","journal-title":"Cell Biochem. Biophys."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1084\/jem.20130505","article-title":"Local BLyS production by T follicular cells mediates retention of high affinity B cells during affinity maturation","volume":"211","author":"Goenka","year":"2014","journal-title":"J. Exp. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1073\/pnas.97.7.3370","article-title":"Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice","volume":"97","author":"Khare","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1084\/jem.190.11.1697","article-title":"Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations","volume":"190","author":"Mackay","year":"1999","journal-title":"J. Exp. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/35010115","article-title":"TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease","volume":"404","author":"Gross","year":"2000","journal-title":"Nature"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e000063","DOI":"10.1136\/lupus-2014-000063","article-title":"BAFF (B cell activating factor) transcript level in peripheral blood of patients with SLE is associated with same-day disease activity as well as global activity over the next year","volume":"2","author":"Zollars","year":"2015","journal-title":"Lupus Sci. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"R109","DOI":"10.1186\/ar2506","article-title":"Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: A phase I trial in patients with systemic lupus erythematosus","volume":"10","author":"Furie","year":"2008","journal-title":"Arthritis Res. Ther."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1002\/art.30613","article-title":"A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1002\/art.34400","article-title":"Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus","volume":"64","author":"Stohl","year":"2012","journal-title":"Arthritis Rheum."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1136\/annrheumdis-2011-200937","article-title":"Belimumab in the treatment of systemic lupus erythematosus: High disease activity predictors of response","volume":"71","author":"Petri","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41572-019-0141-9","article-title":"Lupus nephritis","volume":"6","author":"Anders","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Margiotta, D.P.E., Basta, F., Batani, V., and Afeltra, A. (2018). Belimumab and low-doses of mycophenolate mofetil as induction therapy of class IV lupus nephritis: Case series and literature review. BMC Nephrol., 19.","DOI":"10.1186\/s12882-018-0847-z"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","article-title":"Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis","volume":"383","author":"Furie","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/art.40360","article-title":"Efficacy and Safety of Atacicept in Patients with Systemic Lupus Erythematosus: Results of a Twenty-Four-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Phase IIb Study","volume":"70","author":"Merrill","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1007\/s40265-021-01591-1","article-title":"Telitacicept: First Approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1080\/08923973.2021.1973493","article-title":"Telitacicept as a BLyS\/APRIL dual inhibitor for autoimmune disease","volume":"43","author":"Shi","year":"2021","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/art.34359","article-title":"Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The Lupus Nephritis Assessment with Rituximab study","volume":"64","author":"Rovin","year":"2012","journal-title":"Arthritis Rheum."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1002\/art.38037","article-title":"Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: Results from a randomized, double-blind, phase III study","volume":"65","author":"Mysler","year":"2013","journal-title":"Arthritis Rheum."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1136\/annrheumdis-2021-220920","article-title":"B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: A randomised, double-blind, placebo-controlled trial","volume":"81","author":"Furie","year":"2022","journal-title":"Ann. Rheum Dis."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1093\/rheumatology\/ket129","article-title":"Efficacy and safety of epratuzumab in patients with moderate\/severe flaring systemic lupus erythematosus: Results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up","volume":"52","author":"Wallace","year":"2013","journal-title":"Rheumatology"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/art.39856","article-title":"Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results from Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials","volume":"69","author":"Clowse","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1056\/NEJMoa2023325","article-title":"Targeting CD38 with Daratumumab in Refractory Systemic Lupus Erythematosus","volume":"383","author":"Ostendorf","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1002\/art.22046","article-title":"Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment","volume":"54","author":"Smith","year":"2006","journal-title":"Arthritis Rheum."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/art.40861","article-title":"Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients with Systemic Lupus Erythematosus","volume":"71","author":"Wallace","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1093\/rheumatology\/key042","article-title":"Ofatumumab for B cell depletion in patients with systemic lupus erythematosus who are allergic to rituximab","volume":"57","author":"Masoud","year":"2018","journal-title":"Rheumatology"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1136\/ard.2007.079418","article-title":"B cell depletion therapy in systemic lupus erythematosus: Relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response","volume":"67","author":"Cambridge","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/nrrheum.2016.18","article-title":"The BAFFling effects of rituximab in lupus: Danger ahead?","volume":"12","author":"Ehrenstein","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"R167","DOI":"10.1186\/ar2076","article-title":"Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis","volume":"8","author":"Vallerskog","year":"2006","journal-title":"Arthritis Res. Ther."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jaut.2018.03.003","article-title":"The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus","volume":"91","author":"Kraaij","year":"2018","journal-title":"J. Autoimmun."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/art.41466","article-title":"Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis","volume":"73","author":"SM","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"R74","DOI":"10.1186\/ar1942","article-title":"Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus","volume":"8","author":"Dorner","year":"2006","journal-title":"Arthritis Res. Ther."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.cyto.2013.02.023","article-title":"Increased CD38 expression in T cells and circulating anti-CD38 IgG autoantibodies differentially correlate with distinct cytokine profiles and disease activity in systemic lupus erythematosus patients","volume":"62","author":"Pavon","year":"2013","journal-title":"Cytokine"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.3389\/fimmu.2018.01228","article-title":"Daratumumab for the Treatment of Multiple Myeloma","volume":"9","author":"Plesner","year":"2018","journal-title":"Front Immunol."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Benfaremo, D., and Gabrielli, A. (2019). Is There a Future for Anti-CD38 Antibody Therapy in Systemic Autoimmune Diseases?. Cells, 9.","DOI":"10.3390\/cells9010077"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1136\/annrheumdis-2014-206016","article-title":"The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus","volume":"74","author":"Alexander","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"756941","DOI":"10.3389\/fimmu.2021.756941","article-title":"Clinical Experience of Proteasome Inhibitor Bortezomib Regarding Efficacy and Safety in Severe Systemic Lupus Erythematosus: A Nationwide Study","volume":"12","author":"Walhelm","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.smim.2009.05.012","article-title":"CD40 and autoimmunity: The dark side of a great activator","volume":"21","author":"Peters","year":"2009","journal-title":"Semin. Immunol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/jlb.67.1.2","article-title":"CD40-CD40 ligand","volume":"67","author":"Banchereau","year":"2000","journal-title":"J. Leukoc. Biol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"58","DOI":"10.4049\/jimmunol.1900043","article-title":"Treatment with a CD40 Antagonist Antibody Reverses Severe Proteinuria and Loss of Saliva Production and Restores Glomerular Morphology in Murine Systemic Lupus Erythematosus","volume":"203","author":"Perper","year":"2019","journal-title":"J. Immunol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"5397","DOI":"10.1093\/rheumatology\/keab381","article-title":"Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus","volume":"60","author":"Furie","year":"2021","journal-title":"Rheumatology"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of Anifrolumab in Active Systemic Lupus Erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1038\/s41467-021-23361-z","article-title":"Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus","volume":"12","author":"Hasni","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0140-6736(18)31363-1","article-title":"Baricitinib for systemic lupus erythematosus: A double-blind, randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Wallace","year":"2018","journal-title":"Lancet"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/art.42391","article-title":"Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial","volume":"75","author":"Morand","year":"2023","journal-title":"Arthritis Rheumatol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1002\/art.41811","article-title":"Efficacy, Safety, and Pharmacodynamic Effects of the Bruton\u2019s Tyrosine Kinase Inhibitor Fenebrutinib (GDC-0853) in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled Trial","volume":"73","author":"Isenberg","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"140","DOI":"10.4049\/immunohorizons.2000005","article-title":"Type I IFN Drives Experimental Systemic Lupus Erythematosus by Distinct Mechanisms in CD4 T Cells and B Cells","volume":"4","author":"Klarquist","year":"2020","journal-title":"Immunohorizons"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1021\/ac902406w","article-title":"Phosphorescent oxygen sensors based on nanostructured polyolefin substrates","volume":"82","author":"Gillanders","year":"2010","journal-title":"Anal. Chem."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1136\/annrheumdis-2015-208562","article-title":"Sifalimumab, an anti-interferon-alpha monoclonal antibody, in moderate to severe systemic lupus erythematosus: A randomised, double-blind, placebo-controlled study","volume":"75","author":"Khamashta","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1002\/art.41598","article-title":"Long-Term Safety and Efficacy of Anifrolumab in Adults with Systemic Lupus Erythematosus: Results of a Phase II Open-Label Extension Study","volume":"73","author":"Chatham","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"5854","DOI":"10.1093\/rheumatology\/keab176","article-title":"Exposure-response analysis for selection of optimal dosage regimen of anifrolumab in patients with systemic lupus erythematosus","volume":"60","author":"Chia","year":"2021","journal-title":"Rheumatology"},{"key":"ref_109","first-page":"658","article-title":"FDA approves AstraZeneca\u2019s anifrolumab for lupus","volume":"20","author":"Mullard","year":"2021","journal-title":"Nat. Rev. Drug. Discov."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1002\/art.38047","article-title":"Suppression of glomerulonephritis in lupus-prone NZB x NZW mice by RN486, a selective inhibitor of Bruton\u2019s tyrosine kinase","volume":"65","author":"LaStant","year":"2013","journal-title":"Arthritis Rheum."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1056\/NEJMoa1901981","article-title":"Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis","volume":"380","author":"Montalban","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1056\/NEJMoa2110297","article-title":"Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia","volume":"386","author":"Kuter","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.jaci.2022.08.027","article-title":"Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria","volume":"150","author":"Maurer","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/blood.2019001160","article-title":"Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL","volume":"134","author":"Tam","year":"2019","journal-title":"Blood"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1093\/intimm\/dxf052","article-title":"Partial restoration of B cell development in Jak-3-\/- mice achieved by co-expression of IgH and E\u03bc-myc transgenes","volume":"14","author":"Dillon","year":"2002","journal-title":"Int. Immunol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/art.39818","article-title":"Tofacitinib Ameliorates Murine Lupus and Its Associated Vascular Dysfunction","volume":"69","author":"Furumoto","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jaut.2016.10.005","article-title":"Impact of tofacitinib treatment on human B-cells in vitro and in vivo","volume":"77","author":"Rizzi","year":"2017","journal-title":"J. Autoimmun."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"675542","DOI":"10.3389\/fimmu.2021.675542","article-title":"Tofacitinib Ameliorates Lupus through Suppression of T Cell Activation Mediated by TGF-Beta Type I Receptor","volume":"12","author":"Yan","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1136\/annrheumdis-2013-203756","article-title":"The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells","volume":"73","author":"Kubo","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1217147","DOI":"10.3389\/fmed.2023.1217147","article-title":"Janus kinase inhibitors in systemic lupus erythematosus: Implications for tyrosine kinase 2 inhibition","volume":"10","author":"Nikolopoulos","year":"2023","journal-title":"Front. Med."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41573-020-0082-8","article-title":"Kinase inhibition in autoimmunity and inflammation","volume":"20","author":"Zarrin","year":"2021","journal-title":"Nat. Rev. Drug. Discov."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41467-017-02672-0","article-title":"NF-kappaB inducing kinase is a therapeutic target for systemic lupus erythematosus","volume":"9","author":"Brightbill","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1002\/art.39741","article-title":"Pin1-Targeted Therapy for Systemic Lupus Erythematosus","volume":"68","author":"Wei","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"102582","DOI":"10.1016\/j.jaut.2020.102582","article-title":"The B cell response to both protein and nucleic acid antigens displayed on apoptotic cells are dependent on endosomal pattern recognition receptors","volume":"117","author":"Garimella","year":"2021","journal-title":"J. Autoimmun."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMc2107725","article-title":"CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus","volume":"385","author":"Mougiakakos","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat. Med."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1111\/ajt.12220","article-title":"A single dose of rituximab does not deplete B cells in secondary lymphoid organs but alters phenotype and function","volume":"13","author":"Kamburova","year":"2013","journal-title":"Am. J. Transplant."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1136\/ard.2007.080960","article-title":"Synovial tissue response to rituximab: Mechanism of action and identification of biomarkers of response","volume":"67","author":"Thurlings","year":"2008","journal-title":"Ann. Rheum. Dis."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/19\/6268\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:00:59Z","timestamp":1760130059000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/19\/6268"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,28]]},"references-count":128,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2023,10]]}},"alternative-id":["jcm12196268"],"URL":"https:\/\/doi.org\/10.3390\/jcm12196268","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,28]]}}}